RESEARCH TRIANGLE PARK, NC – December 12, 2013 – Quintiles today announced the appointment of W. Scott Evangelista to serve as president, Integrated Commercial Services and Solutions. In this role, Evangelista is responsible for leading Quintiles’ global Commercial organization and the ongoing development and delivery of its related service offerings.
A veteran of the life sciences industry with more than two decades of experience, Evangelista joins Quintiles from Deloitte Consulting LLP. At Deloitte, Evangelista was a principal in the company’s Life Sciences practice where he served as commercial practice leader. In this role, he worked with biopharmaceutical customers across a spectrum of commercial operations, providing strategic consulting, business development and overall management guidance.
“Scott’s experience working on and developing innovative commercial solutions for the biopharmaceutical industry is a tremendous addition to our already world-class team,” said Tom Pike, chief executive officer, Quintiles. “During his career, Scott has been involved in many aspects of the commercial organization, all while delivering a consistent track record of growth and innovation. He brings a range of expertise and experience that I believe will help take our commercial customer support to the next level.”
Evangelista said, “I am extremely excited to be joining Quintiles and leading a true, world-class commercial organization. The commercial landscape continues to evolve at an incredible pace that requires innovative thinking, diverse expertise and flawless execution. Quintiles is positioned to succeed in this environment, and I look forward to ensuring our team continues to lead and deliver for our commercial customers around the world.”
Before joining Deloitte, Evangelista was the founder and managing partner of the Swiftwater Group, a management consulting firm, and started his career with two other major consulting firms. Evangelista earned his bachelor’s degree in finance and a master’s degree in management information systems from Boston University.
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.